Loading

Navigating the evolving funding landscape for capital intensive CGTs

11 Feb 2026
Theatre 4
Commercial models & partnerships

As CGT development costs rise and capital availability fluctuates, securing investment requires clear value articulation, disciplined portfolio planning, and realistic timelines. This fireside chat explores current financing dynamics, investor priorities, and strategic approaches that support long-term program viability in a complex funding environment.

Key takeaways:

  • Identify funding models suited to capital-intensive CGT development
  • Evaluate investor expectations and due diligence priorities across stages
  • Align scientific milestones with financial planning and risk management
  • Strengthen value communication to improve funding readiness
  • Analyze external market trends that influence CGT investment decisions
Chairperson
Ann-Hunter van Kirk, Senior Equity Analyst - Bloomberg
Speakers
Jeff Liter, President & CEO - Luminary Therapeutics
Daria Fedyukina, Program Manager - ARPA-H